Alarming irregularities in the disposal of valuable land by the Karachi Development Authority have prompted Director General Asif Jan Siddiqui to constitute a 10-member committee to investigate the ...

Last Call: One More for the Road - The Finale is set for June 27, 2026. "I can't think of a better place to put on a big show than in Nashville," Jackson tells PEOPLE Sarah Michaud is the senior news ...

Ferrari owns a rare economic moat in the automotive industry. Ferrari's operating cash flow to sales is sky-high compared to rivals. Ferrari's ROIC suggests the company is great at creating value for ...

Despite possessing a solid data package on the potential of high-dose Sprinraza in spinal muscular atrophy (SMA), Biogen will now need to revise its application if it hopes to secure an FDA nod. The ...

The dine-in breakfast and lunch chain that began franchising in 2019 has 29 locations, 21 of which are company owned. Though Big Biscuit is leaning into corporate development—it’s targeting five ...

Are you ready for it? Taylor Swift is releasing an 89-minute “release party” event alongside her new album, “The Life of a Showgirl,” next month. And it’s only in theaters. “Taylor Swift: The Official ...

Graphs and data visualizations are all around us—charting our steps, our election results, our favorite sports teams’ stats, and trends across our world. But too often, people glance at a graph ...

Abstract: Graph Convolution Networks (GCNs) have achieved remarkable success in representation of structured graph data. As we know that traditional GCNs are generally defined on the fixed first-order ...

Corrections & clarifications: A previous version of this report incorrectly characterized Justinian Huang's "Lucky Seed." The book is his second. Cozy sweaters, warm mugs of tea, curling up by the ...

ON SEPTEMBER 10th Charlie Kirk, a right-wing activist, was shot dead while speaking at a university in Utah. Although a suspect is in custody, the motive of the killer is still unknown. President ...

PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.